Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
450 2 |
Ultima descărcare din IBN: 2021-06-30 07:53 |
SM ISO690:2012 PÂNTEA, Victor. Tratamentul hepatitei virale B cronice cu baraclude (entecavir). In: Sănătate Publică, Economie şi Management în Medicină , 2012, nr. 5(44), pp. 38-43. ISSN 1729-8687. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Sănătate Publică, Economie şi Management în Medicină | ||||||
Numărul 5(44) / 2012 / ISSN 1729-8687 /ISSNe 2587-3873 | ||||||
|
||||||
Pag. 38-43 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
At world level, the infection with hepatic virus B remains to be a major problem of public health, being a frequent cause of evolution to chronic hepatitis, hepatic cirrhosis and hepatocarcinoma. It is thus evident the necessity of an efficient antiviral treatment which ideally should lead to viral clearance. We have the results of 3 trials: 027, 022 and 026, randomized studies and double blind, multicentric, international. The 027 study compares 0,5 mg of Baraclude administered once a day (325 patients) with 100 mg of lamivudine (LVD) administered once a day (313 patients), in patients with chronic hepatitis B AgHBe negative, not treated previously with nucleosides. The 022 study compares 0,5 mg of Baraclude administered once a day (354 patients) with 100 mg of lamivudine administered once a day (355) in patients with chronic hepatitis B AgHBe pozitive untreared previously with nucleosides. The 026 study compares 1,0 mg of Baraclude administered once a day (124) patients with 100 mg of lamivudine administered once a day (116), in patients with chronic hepatitis B resistent to LVD. The 027 study showed that the viral undetectable lood in patients with AgHBe negative not treated previously with nucleosides at 48 weeks in those treated with Baraclude was at about 90% opposite to those treated with lamivudine- 72% the cummulative response rate up to 96 weeks was 94% and 77%; in 022 study the viral undetectable viral lood at 48 weeks in the fi rst lot was 67%,while in the second one 38%. In 026 study the undetectable viral lood in patients resistant to lamivudine in the fi rst lot consisted 19%, while in the second lot only 1% up to 96 weeks, the cummulative rate of undetectable viral lood was 30% opposite to the second lot only 1% |
||||||
Cuvinte-cheie hepatic virus B, lamivudine, baraclude, вирусный гепатит В, ламивудин, бараклуд |
||||||
|